These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 29523487)
1. Therapy with cholesteryl ester transfer protein (CETP) inhibitors and diabetes risk. Masson W; Lobo M; Siniawski D; Huerín M; Molinero G; Valéro R; Nogueira JP Diabetes Metab; 2018 Dec; 44(6):508-513. PubMed ID: 29523487 [TBL] [Abstract][Full Text] [Related]
2. Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. Li C; Zhang W; Zhou F; Chen C; Zhou L; Li Y; Liu L; Pei F; Luo H; Hu Z; Cai J; Zeng C PLoS One; 2013; 8(10):e77049. PubMed ID: 24204732 [TBL] [Abstract][Full Text] [Related]
3. Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. Ference BA; Kastelein JJP; Ginsberg HN; Chapman MJ; Nicholls SJ; Ray KK; Packard CJ; Laufs U; Brook RD; Oliver-Williams C; Butterworth AS; Danesh J; Smith GD; Catapano AL; Sabatine MS JAMA; 2017 Sep; 318(10):947-956. PubMed ID: 28846118 [TBL] [Abstract][Full Text] [Related]
4. [HDL and CETP in atherogenesis]. Pöss J; Böhm M; Laufs U Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258 [TBL] [Abstract][Full Text] [Related]
5. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Nurmohamed NS; Ditmarsch M; Kastelein JJP Cardiovasc Res; 2022 Nov; 118(14):2919-2931. PubMed ID: 34849601 [TBL] [Abstract][Full Text] [Related]
6. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Schaefer EJ Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567 [TBL] [Abstract][Full Text] [Related]
7. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430 [TBL] [Abstract][Full Text] [Related]
9. Cholesteryl ester transfer protein (CETP) inhibitors. Hunt JA; Lu Z Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458 [TBL] [Abstract][Full Text] [Related]
10. Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Taheri H; Filion KB; Windle SB; Reynier P; Eisenberg MJ Cardiology; 2020; 145(4):236-250. PubMed ID: 32172237 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. Trinder M; Wang Y; Madsen CM; Ponomarev T; Bohunek L; Daisely BA; Julia Kong H; Blauw LL; Nordestgaard BG; Tybjærg-Hansen A; Wurfel MM; Russell JA; Walley KR; Rensen PCN; Boyd JH; Brunham LR Circulation; 2021 Mar; 143(9):921-934. PubMed ID: 33228395 [TBL] [Abstract][Full Text] [Related]
12. Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Filippatos TD; Klouras E; Barkas F; Elisaf M Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):953-62. PubMed ID: 27171534 [TBL] [Abstract][Full Text] [Related]
14. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P; J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362 [TBL] [Abstract][Full Text] [Related]
16. Future of cholesteryl ester transfer protein inhibitors. Rader DJ; deGoma EM Annu Rev Med; 2014; 65():385-403. PubMed ID: 24422575 [TBL] [Abstract][Full Text] [Related]
17. Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin. Krikken JA; Waanders F; Dallinga-Thie GM; Dikkeschei LD; Vogt L; Navis GJ; Dullaart RP Expert Opin Ther Targets; 2009 May; 13(5):497-504. PubMed ID: 19397474 [TBL] [Abstract][Full Text] [Related]
18. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Evans M; Roberts A; Davies S; Rees A Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326 [TBL] [Abstract][Full Text] [Related]
19. Cholesteryl ester transfer protein (CETP) deficiency and CETP inhibitors. Mabuchi H; Nohara A; Inazu A Mol Cells; 2014 Nov; 37(11):777-84. PubMed ID: 25410905 [TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion. Kappelle PJ; van Tol A; Wolffenbuttel BH; Dullaart RP Cardiovasc Ther; 2011 Dec; 29(6):e89-99. PubMed ID: 20645987 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]